Watchlist Price Alert

Protalix BioTherapeutics ... (PLX)

AMEX: PLX · Real-Time Price · USD

1.66

0.20 (13.70%)

At close: May 13, 2025, 3:59 PM

1.65

-0.29%

After-hours: May 13, 2025, 07:45 PM EDT

13.70% (1D)

Bid	1.46
Market Cap	131.6M
Revenue (ttm)	53.4M
Net Income (ttm)	2.93M
EPS (ttm)	0.04
PE Ratio (ttm)	41.38
Forward PE	2.05
Analyst	Strong Buy

Ask	1.7
Volume	2,345,681
Avg. Volume (20D)	804,852
Open	1.49
Previous Close	1.46
Day's Range	1.47 - 1.71
52-Week Range	0.82 - 3.10
Beta	-0.05

About PLX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PLX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Protalix BioTherapeutics has released their quartely earnings on May 9, 2025:

Revenue of $10.11M misses estimates by $11.49M, with 169.82% YoY growth.

EPS of -0.05 misses estimates by -0.13, with 16.67% YoY growth.

Why Price Moved

4 days ago

-40.48%

Protalix BioTherapeutics shares are trading lower ... Unlock content with Pro Subscription

1 month ago

+9.38%

Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.

News

4 days ago · seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive Offi...

4 days ago · proactiveinvestors.com

Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth

Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from pos...

1 month ago · seekingalpha.com

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with incre...

1 month ago · proactiveinvestors.com

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI

Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explai...

1 month ago · proactiveinvestors.com

Protalix Biotherapeutics gains momentum: analysts see long-term upside

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's i...

1 month ago · proactiveinvestors.com

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, ...

1 month ago · benzinga.com

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

On Monday, Protalix BioTherapeutics, Inc. PLX reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent.

1 month ago · seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and...

2 months ago · proactiveinvestors.com

Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum

For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- a...